Merck KGaA Q2 EBITDA pre rises 9.4% to € 1.6 billion; net sales increase 3.4% to € 5.43 billion

PUBT · 2d ago
Merck KGaA Q2 EBITDA pre rises 9.4% to € 1.6 billion; net sales increase 3.4% to € 5.43 billion
  • Merck KGaA posted Q2 2026 net sales of € 5.4 billion, up 3.4% year on year; operating result (EBIT) fell 15.5% to € 753 million.
  • Profit after income tax dropped 24.7% to € 494 million; earnings per share slid 24.7% to € 1.13.
  • Non-IFRS EBITDA pre climbed 9.4% to € 1.6 billion, lifting the EBITDA pre margin by 1.6 percentage points to 29.4%.
  • Life Science net sales rose 6.4% to € 2.4 billion, while Electronics slipped 1.7% to € 871 million despite 11.7% organic growth.
  • Guidance was raised to net sales of € 21.0 billion-€ 21.8 billion; non-IFRS EBITDA pre is seen at € 5.9 billion-€ 6.3 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.